Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arts Optical International Holdings Limited (1120.HK)
Kwun Tong, HK
Arts Optical International Holdings Limited operates as an investment holding company with primary involvement in the design, production, and global distribution of eyewear. Its diverse product offerings include prescription spectacle frames, sunglasses, and optical lenses. The firm caters to markets across Europe, the United States, Asia, and various other international territories. These products are marketed and sold under a portfolio of brands such as CEO-V, Dakota Smith, CV, MINIBOXX, PAULO PILIPE, Laura Ashley, RetroCraft, and AustSports. Additionally, the company engages in property holding activities. Founded in 1973, Arts Optical is headquartered in Kwun Tong, Hong Kong.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +10.29% | +2.74% | -9.64% | -21.88% | -9.64% | -21.05% | -35.90% | -7.41% | -2.60% | -75.73% | -20.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+4.0% Q4'25: +17.3% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+81.1% ★ Q4'25: +20.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-8.7% Q4'25: -18.0% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+5.6% Q4'25: +10.4% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+5.0% Q4'25: +22.8% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.07× Q4'25: 0.95× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2011 actual |
Dec 2012 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
547.01M
est: 520.39M (+5.1%)
|
602.52M
est: 773.65M (-22.1%)
|
519.41M
est: 582.37M (-10.8%)
|
684.96M
est: 661.33M (+3.6%)
|
791.62M
est: 615.18M (+28.7%)
|
1.10B
est: 580.84M (+89.2%)
|
1.55B
est: 1.51B (+2.5%)
|
1.48B
est: 1.67B (-11.7%)
|
| EBITDA |
110.34M
est: -26.77M (+512.2%)
|
154.24M
est: -39.01M (+495.3%)
|
129.28M
est: 124.51M (+3.8%)
|
150.05M
est: 155.57M (-3.6%)
|
143.95M
est: 150.94M (-4.6%)
|
194.94M
est: 57.78M (+237.4%)
|
219.46M
est: -77.68M (+382.5%)
|
154.19M
est: -85.93M (+279.4%)
|
| EBIT |
103.37M
est: -50.13M (+306.2%)
|
107.84M
est: -73.06M (+247.6%)
|
84.07M
est: 88.75M (-5.3%)
|
102.18M
est: 103.34M (-1.1%)
|
94.85M
est: 106.12M (-10.6%)
|
138.41M
est: -56.24M (+346.1%)
|
121.70M
est: -145.47M (+183.7%)
|
56.74M
est: -160.91M (+135.3%)
|
| Net Income |
100.15M
est: 116.42M (-14.0%)
|
105.67M
est: 174.86M (-39.6%)
|
82.34M
est: 79.57M (+3.5%)
|
102.80M
est: 93.46M (+10.0%)
|
95.73M
est: 97.03M (-1.3%)
|
163.37M
|
112.21M
|
48.85M
|
| SGA |
68.24M
est: 156.91M (-56.5%)
|
64.08M
est: 228.68M (-72.0%)
|
58.33M
est: 78.44M (-25.6%)
|
84.11M
est: 96.64M (-13.0%)
|
91.94M
est: 116.16M (-20.9%)
|
112.60M
est: 118.02M (-4.6%)
|
239.66M
est: 455.30M (-47.4%)
|
241.88M
est: 503.64M (-52.0%)
|
| EPS |
0.29
est: 0.30 (-3.8%)
|
0.28
est: 0.45 (-38.5%)
|
0.22
est: 0.25 (-10.2%)
|
0.27
est: 0.28 (-2.7%)
|
0.25
|
0.43
|
0.29
|
0.13
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hoi Ying Ng | Founder & Executive Chairman | 2M | male |
| Yat Shan Ng | Chief Executive Officer & Executive Director | 1M | female |
| Kim Ying Ng | Executive Director | 476.0K | male |
| Zhihong Wu | Executive Director | 476.0K | female |
| Chung Wah Chu | Deputy Chief Executive Officer | — | male |
| Pui Yiu Choi | Group Chief Financial Officer & Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1120.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
